Ticstop 12.5 Tablet Tablet

About Ticstop 12.5 Tablet

Ticstop 12.5 Tablet is a tablet from Square Pharmaceuticals PLC., with the generic name Tetrabenazine. Ticstop 12.5 Tablet is used to treat chorea associated with Huntington's disease.

There are 4 brands of Tetrabenazine listed in Bangladesh. By unit price, Ticstop 12.5 Tablet is among the cheapest of them.

What is Ticstop 12.5 Tablet?

Made by Square Pharmaceuticals PLC., Ticstop 12.5 Tablet is a tablet whose active ingredient is Tetrabenazine. It is prescribed for chorea linked to Huntington's disease, where unwanted jerky movements affect daily life. It belongs to a group of medicines called atypical neuroleptic drugs. Use it only as your doctor directs.

Uses of Ticstop 12.5 Tablet

Ticstop 12.5 Tablet is used to treat chorea associated with Huntington's disease. It is not a general treatment for other movement problems. Ask the doctor if you are unsure why it has been prescribed for you. The doctor decides whether it is suitable and how it fits into overall care.

How to use Ticstop 12.5 Tablet

Swallow it as directed, and do not change the amount or stop suddenly on your own. Swallow the tablet with water. Ticstop 12.5 Tablet is taken by mouth. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of Ticstop 12.5 Tablet

Tell the doctor promptly if you notice low mood, thoughts of self-harm, or any movement or swallowing problems. Because of these, the doctor monitors the person closely. Like other medicines, Ticstop 12.5 Tablet can have side effects. Ask your doctor or pharmacist about any side effect that worries you. The doctor will decide how to manage any side effect.

Safety and precautions

It can worsen parkinsonism, so caution is needed. It may worsen parkinsonism, so tell the doctor about any such condition. Ticstop 12.5 Tablet should not be used by people who are actively suicidal or who have untreated or poorly treated depression, by people with liver problems, or by people taking monoamine oxidase inhibitors. Keep out of reach of children.

Frequently asked questions

Why is Ticstop 12.5 Tablet prescribed?

Ticstop 12.5 Tablet is used to treat chorea associated with Huntington's disease. It is not a general treatment for other movement problems.

How should I take Ticstop 12.5 Tablet?

Swallow it as directed, and do not change the amount or stop suddenly on your own. Swallow the tablet with water.

Can Ticstop 12.5 Tablet cause side effects?

Tell the doctor promptly if you notice low mood, thoughts of self-harm, or any movement or swallowing problems. Because of these, the doctor monitors the person closely.

Is Ticstop 12.5 Tablet safe for everyone?

It can worsen parkinsonism, so caution is needed. It may worsen parkinsonism, so tell the doctor about any such condition.

Indications

Tetrabenazine is indicated for the treatment of chorea associated with Huntington's disease.

Pharmacology

Prolongation of the QTc interval has been observed at doses of 50 mg. In rats, it has been observed that tetrabenazine or its metabolites bind to melanin-containing tissues such as the eyes and skin. After a single oral dose of radiolabeled tetrabenazine, radioactivity was still detected in eye and fur at 21 days post dosing.

Tetrabenazine is a reversible human vesicular monoamine transporter type 2 inhibitor (Ki = 100 nM). It acts within the basal ganglia and promotes depletion of monoamine neurotransmitters serotonin, norepinephrine, and dopamine from stores. It also decreases uptake into synaptic vesicles. Dopamine is required for fine motor movement, so the inhibition of its transmission is efficacious for hyperkinetic movement. Tetrabenazine exhibits weak in vitro binding affinity at the dopamine D2 receptor (Ki = 2100 nM).

Dosage & Administration

General Dosing Considerations:

The chronic daily dose of Tetrabenazine used to treat chorea associated with Huntington's disease (HD) is determined individually for each patient. When first prescribed, Tetrabenazine therapy should be titrated slowly over several weeks to identify a dose of XENAXINE that reduces chorea and is tolerated. Tetrabenazine can be administered without regard to food.

Individualization Of Dose:

Dosing Recommendations Up to 50 mg per day: The starting dose should be 12.5 mg per day given once in the morning. After one week, the dose should be increased to 25 mg per day given as 12.5 mg twice a day. Tetrabenazine should be titrated up slowly at weekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces chorea. If a dose of 37.5 to 50 mg per day is needed, it should be given in a three times a day regimen. The maximum recommended single dose is 25 mg. If adverse reactions such as akathisia, restlessness, parkinsonism, depression, insomnia, anxiety or sedation occur, titration should be stopped and the dose should be reduced. If the adverse reaction does not resolve, consideration should be given to withdrawing Tetrabenazine treatment or initiating other specific treatment (e.g., antidepressants).

Dosing Recommendations Above 50 mg per day: Patients who require doses of Tetrabenazine greater than 50 mg per day should be first tested and genotyped to determine if they are poor metabolizers (PMs) or extensive metabolizers (EMs) by their ability to express the drug metabolizing enzyme, CYP2D6. The dose of Tetrabenazine should then be individualized accordingly to their status as PMs or EMs

Extensive and Intermediate CYP2D6 Metabolizers:

Genotyped patients who are identified as extensive (EMs) or intermediate metabolizers (IMs) of CYP2D6, who need doses of Tetrabenazine above 50 mg per day, should be titrated up slowly at weekly intervals by 12.5 mg daily, to allow the identification of a tolerated dose that reduces chorea. Doses above 50 mg per day should be given in a three times a day regimen. The maximum recommended daily dose is 100 mg and the maximum recommended single dose is 37.5 mg. If adverse reactions such as akathisia, parkinsonism, depression, insomnia, anxiety or sedation occur, titration should be stopped and the dose should be reduced. If the adverse reaction does not resolve, consideration should be given to withdrawing Tetrabenazine treatment or initiating other specific treatment (e.g., antidepressants)

Interaction

Tetrabenazine should not be given with or within 14 days of discontinuation of MAOI therapy. Blocks action of reserpine. Decreases effects of levodopa and worsen parkinsonism. Increased risk of extrapyramidal side effects when given with amantadine, metoclopramide, antipsychotics.

Contraindications

Tetrabenazine is contraindicated in patients:
  • Who are actively suicidal, or in patients with untreated or inadequately treated depression 
  • With hepatic impairment 
  • Taking monoamine oxidase inhibitors (MAOIs). XENAZINE should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI 

Side Effects

The following serious adverse reactions are Depression, Suicidality Akathisia, restlessness, and agitation, Parkinsonism, Dysphagia, Sedation and somnolence

Pregnancy & Lactation

Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Tetrabenazine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: It is not known whether Tetrabenazine or its metabolites are excreted in human milk. Since many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from Tetrabenazine, a decision should be made whether to discontinue nursing or to discontinue Tetrabenazine, taking into account the importance of the drug to the mother.

Precautions & Warnings

May exacerbate symptoms of parkinsonism. Caution to be exercised when driving or performing skilled tasks. Pregnancy.

Overdose Effects

Three episodes of overdose occurred in the open-label trials performed in support of registration. Eight cases of overdose with Tetrabenazine have been reported in the literature. The dose of Tetrabenazine in these patients ranged from 100 mg to 1g. Adverse reactions associated with Tetrabenazine overdose include acute dystonia, oculogyric crisis, nausea and vomiting, sweating, sedation, hypotension, confusion, diarrhea, hallucinations, rubor, and tremor.

Treatment should consist of those general measures employed in the management of overdosage with any CNS-active drug. General supportive and symptomatic measures are recommended. Cardiac rhythm and vital signs should be monitored. In managing overdosage, the possibility of multiple drug involvement should always be considered. The physician should consider contacting a poison control center on the treatment of any overdose.

Alternative brands of Tetrabenazine

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.